Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford Biomedica for LentiVector Platform

 Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford Biomedica for LentiVector Platform

Juno Therapeutics Signs License and Clinical Supply Agreement with Oxford Biomedica for LentiVector Platform

Shots:

  • Oxford Biomedica to receive $10M up front in cash, ~$86M as development and regulatory milestones, ~ $131M as commercial milestones and royalties on sales of products developed by Juno Therapeutics utilizing the LentiVector platform
  • Oxford Biomedica will also receive payments from process development and scale-up projects as well as relating to the GMP manufacture of lentiviral vectors for use in clinical trials. Additionally, Juno gets access to Oxford’s new 7,800 m2 manufacturing centre, OxBox and allow it to initiate additional projects in the future
  • The LSA provides Juno a non-exclusive license to Oxford’s LentiVector platform for its application in CAR-T and TCR-T programs in oncology and other indications and additionally enters into a 5yrs. clinical supply agreement that can be extended further

Click here ­to­ read full press release/ article | Ref: Oxford Biomedica | Image: Juno Therapeutics

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post